Tesamorelin

Tesamorelin is a full-length GHRH analog (44 amino acids) that binds with high affinity to the GHRH receptor (GHRHR), a G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary gland. Upon receptor binding, tesamorelin activates adenylyl cyclase through the Gs alpha subunit, increasing intracellular cyclic AMP (cAMP). This triggers protein kinase A (PKA) activation, which drives both immediate GH vesicle exocytosis and transcriptional upregulation of the GH gene, producing both acute GH release and sustained enhancement of the pituitary's GH-producing capacity.

The trans-3-hexenoic acid modification at the N-terminus of tesamorelin protects the first amino acid from cleavage by dipeptidylpeptidase-IV (DPP-IV), the enzyme that rapidly degrades native GHRH. This chemical stabilization extends tesamorelin's plasma half-life to approximately 26-38 minutes after subcutaneous injection, compared to roughly 7 minutes for endogenous GHRH. While this is far shorter than CJC-1295 with DAC (half-life 5.8-8.1 days), it is sufficient to produce a robust and sustained GH pulse from each injection.

Tesamorelin preserves the natural GH regulatory architecture. Somatostatin, the hypothalamic hormone that suppresses GH release, continues to function as a negative feedback brake. This means the body cannot be driven into GH excess through tesamorelin: when GH levels rise, somatostatin activity increases to blunt further release (PMID: 28400207). GH secreted in response to tesamorelin stimulates hepatic IGF-1 production, which mediates downstream effects including lipolysis in visceral adipose tissue, protein synthesis in muscle, and various metabolic and cognitive signaling functions. The visceral fat-specific reduction observed in trials is consistent with visceral adipocytes' high sensitivity to GH-driven lipolysis.

Tesamorelin vs Sermorelin: Both are GHRH receptor agonists, but tesamorelin is the full-length 44-amino acid peptide (matching endogenous GHRH) while sermorelin is the minimum active fragment (29 amino acids). Tesamorelin has FDA approval for an active indication; sermorelin had FDA approval that was voluntarily discontinued for commercial reasons. Tesamorelin's N-terminal modification extends its half-life to 26-38 minutes vs sermorelin's 10-20 minutes, though both require daily injections. Tesamorelin has more rigorous clinical trial data in adults, including two large Phase 3 trials. Sermorelin is more widely available through compounding pharmacies and less expensive.

Tesamorelin vs CJC-1295: Both target the GHRH receptor. CJC-1295 with DAC has a dramatically longer half-life (5.8-8.1 days) through albumin binding, allowing weekly dosing. Tesamorelin requires daily injections. Tesamorelin has FDA approval and published Phase 3 data; CJC-1295 was never FDA-approved and was placed on the restricted Category 2 list in 2023. For visceral fat reduction specifically, tesamorelin has the strongest evidence base of any GHRH analog.

Tesamorelin vs HGH: Tesamorelin stimulates the pituitary to produce GH naturally, preserving somatostatin feedback and pulsatile secretion patterns. Direct HGH (somatropin) bypasses these controls, producing flat, supraphysiologic levels that suppress the body's own production. HGH is a controlled substance; tesamorelin is not. HGH produces faster and more dramatic results but carries higher side-effect risk and cost. For visceral fat reduction, tesamorelin's Phase 3 data shows comparable efficacy to HGH studies in HIV lipodystrophy patients.

Community interest in tesamorelin for off-label use has grown significantly given its FDA approval status, which provides more regulatory certainty than other GH secretagogues. Users pursuing visceral fat reduction report it as notably more effective than sermorelin for abdominal fat specifically, consistent with the trial data. The 15-18% VAT reduction figure from Phase 3 trials is frequently cited in anti-aging communities as a meaningful benchmark. Cost is the primary barrier: commercial pharmacy pricing at $1,000-1,500/month is prohibitive for most, making compounded tesamorelin ($200-400/month through telehealth providers) the practical access point.

The cognitive health findings (PMID: 22869065) have generated interest among users primarily seeking neuroprotective or cognitive enhancement effects rather than body composition changes. Community protocols for cognitive applications tend to use lower doses (0.5-1 mg daily) than the lipodystrophy approval (2 mg daily), closer to the doses used in the cognitive trial. Sleep quality improvement and vivid dreams are commonly reported, consistent with GH-class effects. The requirement for ongoing daily administration (fat returns within 12 weeks of stopping) is consistently noted as a practical consideration vs one-time interventions.